Tonix Pharmaceuticals Holding Corp’s filing revealed that its Chief Executive Officer LEDERMAN SETH acquired Company’s shares for reported $86200.0 on May 15 ’25. In the deal valued at $21.55 per share,4,000 shares were bought. As a result of this transaction, LEDERMAN SETH now holds 4,005 shares worth roughly $0.13 million.
Noble Capital Markets initiated its Tonix Pharmaceuticals Holding Corp [TNXP] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including ROTH Capital’s analysts, who increased its forecast for the stock in mid April from “a Neutral” to “a Buy”. ROTH Capital also remained covering TNXP and has increased its forecast on August 18, 2017 with a “Buy” recommendation from previously “Neutral” rating. ROTH Capital revised its rating on September 07, 2016. It rated TNXP as “a Neutral” which previously was an “a Buy”.
Price Performance Review of TNXP
On Friday, Tonix Pharmaceuticals Holding Corp [NASDAQ:TNXP] saw its stock fall -7.41% to $31.98. Over the last five days, the stock has lost -21.33%. Tonix Pharmaceuticals Holding Corp shares have fallen nearly -3.03% since the year began. Nevertheless, the stocks have fallen -84.99% over the past one year. While a 52-week high of $137.25 was reached on 01/28/25, a 52-week low of $6.76 was recorded on 03/04/25.
Levels Of Support And Resistance For TNXP Stock
The 24-hour chart illustrates a support level at 30.76, which if violated will result in even more drops to 29.53. On the upside, there is a resistance level at 33.95. A further resistance level may holdings at 35.91.
How much short interest is there in Tonix Pharmaceuticals Holding Corp?
A steep rise in short interest was recorded in Tonix Pharmaceuticals Holding Corp stocks on 2025-05-30, growing by 80203.0 shares to a total of 1.06 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 0.98 million shares. There was a rise of 7.59%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 17, 2016 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $10.
